TG Therapeutics, Inc.
TGTXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, TG Therapeutics, Inc. (TGTX) is listed under Biotechnology. The $8.57B market capitalization puts TGTX squarely in mid-cap range for its industry. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Market Cap
$8.57B
Beta
1.66
P/E (TTM)
20.43
P/E (Fwd)
18.88
EPS (TTM)
$2.74
EPS (Fwd)
$2.96
ROE
100.3%
ROA
7.3%
Cash
$552.2M
Total Debt
$754.4M
Free CF
$59.1M
52W Change
75.0%
Annual Financials
Cash vs Debt
Where TGTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TGTX finished 37.34% above its 150-day moving average ($41.43) and 46.80% above its 200-day moving average ($38.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TGTX overbought or oversold?
At the September 3, 2026 close, TGTX's RSI(14) was 76.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $552.2M in cash, though total debt stands at $754.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $59.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 100.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.8M (2022) to $616.3M (2025), reflecting a 22029% increase over the period.
A beta of 1.66 means TGTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for TG Therapeutics, Inc. and its sector.